Latest Breaking News On - Breathing institute - Page 3 : comparemela.com

The teens who made Colorado No. 1 in underage vaping 5 years ago are now young adults, and they're still using

“We're seeing increases in those young adults. They weren't able to stop.”

Maintenance therapy appears underused prior to asthma exacerbations

Nintedanib Under Review for Children With Fibrosing Interstitial Lung Disease

The FDA has accepted the sNDA for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung disease.

Multidisciplinary Care Program Streamlines Pediatric-to-Adult Transition

Program streamlined pediatric-to-adult transition care for the most complex patients at a single institution.

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at.